Quanterix Corporation logo
Quanterix Corporation QTRX
$ 3.38 -3.15%
report update icon

Quarterly report 2026-Q1
added 05-06-2026

Quanterix Corporation Income Statement 2025-2011 | QTRX

Brief overview of financial performance at Quanterix Corporation

The conclusions below are based on five years of reported results. Quanterix Corporation reported revenue of $86.4 million in 2020 and $139 million by 2025. Overall revenue changed by +60.8%, equal to an annualized rate of about 10%. This represents moderate business growth.

Gross profit was $48.2 million at the start and $65 million at the end of the period (+34.8%). The relationship between sales and direct costs deteriorated. Gross margin moved from 55.8% to 46.8%. A lower margin indicates deterioration in the economics of the core business.

EBITDA changed from −$27.3 million to −$110 million (−302.2%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was −31.6% at the start and −79% at the end. The business retained less EBITDA from each unit of revenue.

Net income moved from −31.5 million dollars at the start to −107 million dollars at the end. The period ended with a larger loss than it began with.

The market value of the business moved from $2.2 billion to $269 million, or −88%. Financial performance is stronger than the share-price trend.

Conclusion

The results contain several connected negative signals. The strongest signals are a larger revenue base. The main areas of concern are weaker gross profitability, weaker operating efficiency and limited operating profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Quanterix Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

269 M 242 M 893 M 483 M 1.21 B 2.24 B 767 M 463 M 456 M - - - - - -

Shares

42.6 M 38.4 M 37.6 M 37 M 36 M 29.6 M 28.1 M 22.4 M 21.7 M - - - - - -

Historical Prices

6.32 6.32 23.8 13.1 33.7 75.8 22.8 24.7 20.9 - - - - - -

Net Income

-107 M -38.5 M -28.4 M -99.6 M -57.7 M -31.5 M -40.8 M -31.5 M -27 M -23.2 M -15.9 M - - - -

Revenue

139 M 137 M 122 M 106 M 111 M 86.4 M 56.7 M 37.6 M 22.9 M 17.6 M 12.2 M - - - -

Cost of Revenue

73.9 M 54.3 M 48.1 M 60.2 M 48.8 M 38.2 M 29.9 M 19.7 M 12.9 M 9.84 M - - - - -

Gross Profit

65 M 83.1 M 74.2 M 45.4 M 61.7 M 48.2 M 26.8 M 17.9 M 9.99 M 7.75 M 5.72 M - - - -

Operating Income

-126 M -52.6 M -46 M -104 M -58.6 M -31.6 M -41.6 M -31.6 M -26 M -21.7 M - - - - -

Interest Expense

157 K -136 K 2.52 M -277 K 1.26 M -49 K -10 K -7 K -63 K -164 K - - - - -

EBITDA

-110 M -46.2 M -39.7 M -98.9 M -53.7 M -27.3 M -38.6 M -30.2 M -25.5 M -21.3 M -14.1 M - - - -

Operating Expenses

191 M 136 M 120 M 150 M 120 M 79.8 M 68.4 M 49.5 M 36 M 29.5 M 20.2 M - - - -

General and Administrative Expenses

138 M 102 M 89.1 M 91.9 M 92.3 M 59.6 M 52.2 M 33.7 M 19.7 M 12.5 M 10.2 M - - - -

All numbers in USD currency

Quarterly Income Statement Quanterix Corporation

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

47 M 46.1 M 38.9 M 38.7 M 38.5 M 38.4 M 38.3 M 38.1 M 38 M 37.7 M 37.5 M 37.3 M 37.3 M 37 M 36.9 M 36.9 M 36.8 M 36.5 M 36.3 M 34.4 M 31.7 M 30.1 M 28.3 M 28.2 M 28 M 26.6 M 23.2 M 22.4 M 22.2 M 22.1 M 21.9 M 21.8 M 7.73 M 2.48 M 2.42 M 2.36 M - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-17.5 M -33.5 M -30 M -20.5 M - -8.35 M -7.39 M -11.2 M - -7.76 M -6.06 M -6.1 M - -35.1 M -24.9 M -18.2 M - -15.7 M -11.9 M -10.1 M -9.82 M 2.2 M -12.3 M -11.6 M -11 M -9.87 M -10.6 M -9.4 M -9.33 M -7.66 M -7.34 M -7.2 M -7.38 M -6.61 M -6.63 M -6.39 M - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

36.4 M 40.2 M 24.5 M 30.3 M - 35.8 M 34.4 M 32.1 M - 31.3 M 31 M 28.5 M - 26.6 M 23.5 M 29.6 M - 27.7 M 25.4 M 27.2 M 26.1 M 31.4 M 13.1 M 15.7 M 15.9 M 14.9 M 13.5 M 12.3 M 10.9 M 10.6 M 8.64 M 7.52 M 6.59 M 5.73 M 5.21 M 5.34 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

20.8 M 23 M 13.2 M 13.9 M - 15.7 M 12.1 M 13.5 M - 13.6 M 11.9 M 11.5 M - 15.7 M 14.8 M 15 M - 12.4 M 11.5 M 10.9 M 11.1 M 10.3 M 7.92 M 8.91 M 9.05 M 7.91 M 6.6 M 6.33 M 5.67 M 5 M 4.67 M 4.35 M - 3.17 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

15.6 M 17.2 M 11.3 M 16.4 M - 20.2 M 22.2 M 18.5 M - 17.8 M 19.1 M 16.9 M - 10.9 M 8.71 M 14.6 M - 15.2 M 13.9 M 16.3 M 15 M 21.1 M 5.21 M 6.81 M 6.86 M 7.03 M 6.93 M 6.01 M 5.21 M 5.6 M 3.97 M 3.17 M - 2.56 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-41.4 M -37.3 M -37.1 M -26.4 M - -11.7 M -10.9 M -15.2 M - -13.8 M -9.56 M -9.42 M - -36.6 M -25 M -18.2 M - -15.2 M -13.7 M -9.79 M -9.93 M 2.28 M -12.2 M -11.7 M -11.5 M -10.2 M -10.5 M -9.36 M -9.41 M -7.66 M -7.31 M -7.16 M -7.09 M -6.39 M -6.47 M -6.06 M - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

21.4 M -178 K 49 K 61 K - 5 K -9 K 226 K - 2.03 M -154 K 8 K - -101 K -358 K -217 K - -305 K 1.98 M -194 K 155 K -26 K -11 K -167 K 139 K -34 K -68 K -47 K 81 K -25 K -48 K 24 K -73 K 13 K 77 K 255 K - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-35.8 M -34.3 M -36.5 M -24.2 M - -10.7 M -10.5 M -13.6 M - -8.98 M - -7.98 M - -32.4 M -22.2 M -16.8 M - -11.7 M -11.3 M -8.64 M -9.93 M 5.46 M -10.1 M -10.7 M -11.5 M -8.06 M -9.56 M -8.95 M -9.41 M -6.64 M -6.7 M -6.89 M -7.09 M -6.05 M -6.25 M -5.95 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

56.9 M 54.5 M 48.4 M 42.8 M - 31.9 M 33.2 M 33.7 M - 31.6 M 28.7 M 26.3 M - 47.5 M 33.7 M 32.7 M - 30.5 M 27.5 M 26.1 M - 18.8 M 17.4 M 18.5 M - 17.3 M 17.4 M 15.4 M - 13.3 M 11.3 M 10.3 M - 8.95 M 11.7 M 11.4 M - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

29.8 M 39.1 M 31.4 M 32.5 M - 22.9 M 24.1 M 26 M - 23.6 M 21.6 M 20.8 M - 20 M 27 M 25.7 M - 23.7 M 20.8 M 19.5 M 18.8 M 13.5 M 13.1 M 14.3 M 14 M 13.4 M 13.4 M 11.5 M 10.6 M 8.85 M 7.58 M 6.69 M 6.05 M 4.73 M 4.75 M 4.17 M - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Quanterix Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Myomo Myomo
MYO
$ 0.93 -3.11 % $ 38.9 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 7.24 -0.14 % $ 219 M canadaCanada
AxoGen AxoGen
AXGN
$ 41.37 0.53 % $ 1.91 B usaUSA
AVITA Medical AVITA Medical
RCEL
$ 4.44 -3.69 % $ 124 M australiaAustralia
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 61.74 -1.86 % $ 9.37 B usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 32.66 0.31 % $ 28.3 B britainBritain
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 27.4 -1.23 % $ 627 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 18.59 4.67 % $ 1.26 B usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.14 -2.68 % $ 400 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.86 -1.95 % $ 14.6 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 11.65 -2.27 % $ 453 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 10.95 -1.62 % $ 453 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.35 -4.32 % $ 21.8 M usaUSA
LENSAR LENSAR
LNSR
$ 5.25 -1.87 % $ 62.8 M usaUSA
Beyond Air Beyond Air
XAIR
$ 5.51 0.92 % $ 45.7 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.43 0.14 % $ 60 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 97.15 1.46 % $ 19.2 B usaUSA